Ivor Royston is the founder of Viracta Therapeutics. Viracta Therapeutics has raised $83M in total funding. Latest round: Series D.
Ivor Royston served as the founding President and CEO of Viracta Therapeutics, a precision oncology company focused on treating virus-associated malignancies, from 2015 until September 2022. The company, formerly based in Cardiff, CA, is no longer operating. Royston previously co-founded Hybritech, Inc., which developed the PSA test, and IDEC Corporation, which developed Rituxan. He also served as a Managing Partner at Forward Ventures, a life science venture capital firm, from 1990 to 2017.
Full founder directory · Investor directory · Company funding database · Fundraising library